Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress and promise for the MDMA drug development program.

Allison A Feduccia1, Julie Holland2, Michael C Mithoefer3

  • 1MAPS Public Benefit Corporation, 1115 Mission St, Santa Cruz, CA, 95060, USA. alli@mapsbcorp.com.

Psychopharmacology
|November 21, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.

BMJ open·2026
Same author

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Journal of psychopharmacology (Oxford, England)·2025
Same author

Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

Psychopharmacology·2024
Same author

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology·2024
Same author

Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

Psychopharmacology·2024
Same author

Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.

European journal of psychotraumatology·2024
Same journal

Sotagliflozin pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities and modulates the gut microbiota-immune-brain axis.

Psychopharmacology·2026
Same journal

GlyT1 inhibition enhances working memory in the mouse TUNL task and normalizes NMDA antagonist-induced network activity.

Psychopharmacology·2026
Same journal

Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

Psychopharmacology·2026
Same journal

Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

Psychopharmacology·2026
Same journal

Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

Psychopharmacology·2026
Same journal

Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

Psychopharmacology·2026
See all related articles

3,4-methylenedioxymethamphetamine (MDMA) shows promise in enhancing psychotherapy for posttraumatic stress disorder (PTSD). Clinical trials suggest MDMA-assisted therapy offers favorable safety and significant effect sizes, warranting further investigation.

Area of Science:

  • Psychopharmacology
  • Neuroscience
  • Clinical Psychology

Background:

  • Current pharmacotherapy for PTSD offers limited definitive treatment and often causes problematic side effects.
  • Trauma-focused psychotherapies are effective for PTSD remission but suffer from high dropout rates and limited efficacy in some patients.
  • Investigating adjuncts to psychotherapy is crucial for improving PTSD treatment outcomes.

Purpose of the Study:

  • To evaluate 3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to enhance psychotherapy effectiveness for posttraumatic stress disorder (PTSD).
  • To assess the safety and efficacy of MDMA-assisted psychotherapy.
  • To explore the neural mechanisms underlying MDMA's effects on psychological processing in PTSD.

Main Methods:

  • Phase 2 clinical trials involving MDMA-assisted psychotherapy for PTSD.
Keywords:
3,4-MethylenedioxymethamphetamineMDMAPTSDPsychoactive effects

Related Experiment Videos

  • Utilizing brain imaging techniques and animal models of fear extinction.
  • Administering MDMA on a limited number of occasions in conjunction with psychotherapy.

    • Main Results:

    • Phase 2 trials demonstrated favorable safety outcomes for MDMA-assisted psychotherapy.
    • Observed large effect sizes indicate significant potential for MDMA in treating PTSD.
    • Results support the progression to multi-site phase 3 clinical trials.

    Conclusions:

    • MDMA shows significant promise as an adjunct to psychotherapy for PTSD treatment.
    • Further research is needed to fully understand the complexities of MDMA's effects and PTSD.
    • MDMA-assisted psychotherapy represents a potential advancement in PTSD therapeutic strategies.